Literature DB >> 26431466

Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine.

Yu Bin Seo1, Jacob Lee1, Joon Young Song2, Hee Jung Choi3, Hee Jin Cheong2, Woo Joo Kim2.   

Abstract

Several studies have reported poor immune responses to conventional influenza vaccines in HIV-infected individuals. This study sought to elicit more potent immunogenicity in HIV-infected adults using an intradermal vaccine compared with a conventional intramuscular vaccine. This multicenter, randomized, controlled, open-label study was conducted at 3 university hospitals during the 2011/2012 pre-influenza season. Three vaccines were used in HIV-infected adults aged 18 - 60 years: an inactivated intramuscular vaccine (Agrippal), a reduced-content intradermal vaccine (IDflu9μg) and a standard-content intradermal vaccine (IDflu15μg). Serum hemagglutination-inhibiting (HI) antibodies and INF-γ ELISpot assay were measured at the time of vaccination and 1 month after vaccination. Adverse events were recorded for 7 d. A total of 28 Agrippal, 30 IDflu9μg, and 28 IDflu15μg volunteers were included in this analysis. One month after vaccination, the GMTs and differences in INF-γ ELISpot assay results were similar among the 3 groups. Seroprotection rates, seroconversion rates and mean fold increases (MFI) among the 3 groups were also similar, at approximately 80%, 50-60% and 2.5 - 10.0, respectively. All three vaccines satisfied the CHMP criteria for the A/H1N1 and A/H3N2 strains, but not those for the B strain. In univariate analysis, no demographic or clinical factors, including age, CD4+ T-cell counts, HIV viral load, ART status and vaccine type, were related to failure to achieve seroprotection. The three vaccines were all well-tolerated and all reported reactions were mild to moderate. However, there was a tendency toward a higher incidence of local and systemic reactions in the intradermal vaccine groups. The intradermal vaccine did not result in higher immunogenicity compared to the conventional intramuscular vaccine, even with increased antigen dose.

Entities:  

Keywords:  HIV; immunogenicity; influenza vaccine; intradermal vaccine; safety

Mesh:

Substances:

Year:  2016        PMID: 26431466      PMCID: PMC5049744          DOI: 10.1080/21645515.2015.1076599

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  25 in total

Review 1.  A systematic review of intradermal influenza vaccines.

Authors:  Flora Young; Fawziah Marra
Journal:  Vaccine       Date:  2011-10-01       Impact factor: 3.641

2.  Dose sparing with intradermal injection of influenza vaccine.

Authors:  Richard T Kenney; Sarah A Frech; Larry R Muenz; Christina P Villar; Gregory M Glenn
Journal:  N Engl J Med       Date:  2004-11-03       Impact factor: 91.245

3.  Influenza virus-stimulated generation of anti-human immunodeficiency virus (HIV) activity after influenza vaccination in HIV-infected individuals and healthy control subjects.

Authors:  L A Pinto; V Blazevic; S A Anderson; D J Venzon; C M Trubey; T Rowe; J M Katz; D Liewehr; M J Dolan; G M Shearer
Journal:  J Infect Dis       Date:  2001-03-01       Impact factor: 5.226

4.  The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine.

Authors:  P G Miotti; K E Nelson; G A Dallabetta; H Farzadegan; J Margolick; M L Clements
Journal:  JAMA       Date:  1989-08-11       Impact factor: 56.272

5.  Compromised B cell responses to influenza vaccination in HIV-infected individuals.

Authors:  Angela Malaspina; Susan Moir; Susan M Orsega; Joshua Vasquez; Natalie J Miller; Eileen T Donoghue; Shyamasundaran Kottilil; Misrak Gezmu; Dean Follmann; Galina M Vodeiko; Roland A Levandowski; JoAnn M Mican; Anthony S Fauci
Journal:  J Infect Dis       Date:  2005-03-24       Impact factor: 5.226

6.  Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults.

Authors:  Nancy F Crum-Cianflone; Lynn E Eberly; Chris Duplessis; Jason Maguire; Anuradha Ganesan; Dennis Faix; Gabriel Defang; Yun Bai; Erik Iverson; Tahaniyat Lalani; Timothy Whitman; Patrick J Blair; Carolyn Brandt; Grace Macalino; Timothy Burgess
Journal:  Clin Infect Dis       Date:  2010-12-07       Impact factor: 9.079

7.  Humoral and cellular immune responses to influenza vaccine in patients with advanced cirrhosis.

Authors:  Hee-Jin Cheong; Joon-Young Song; Jeong-Won Park; Jong-Eun Yeon; Kwan-Soo Byun; Chang-Hong Lee; Hyun-Il Cho; Tai-Gyu Kim; Woo-Joo Kim
Journal:  Vaccine       Date:  2005-12-19       Impact factor: 3.641

8.  Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.

Authors:  Filippo Ansaldi; Laura Valle; Daniela de Florentiis; Valentina Parodi; Giuseppe Murdaca; Bianca Bruzzone; Paolo Durando; Maurizio Setti; Giancarlo Icardi
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

9.  Antibody response to tetravalent influenza subunit vaccine in patients infected with human immunodeficiency virus type 1.

Authors:  M M Schneider; M J Sprenger; I M Hoepelman; Y van der Graaf; J C Borleffs
Journal:  Int J Antimicrob Agents       Date:  1996-04       Impact factor: 5.283

Review 10.  Designing vaccines based on biology of human dendritic cell subsets.

Authors:  Karolina Palucka; Jacques Banchereau; Ira Mellman
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

View more
  4 in total

Review 1.  Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I.

Authors:  Nancy F Crum-Cianflone; Eva Sullivan
Journal:  Infect Dis Ther       Date:  2017-08-04

Review 2.  Influenza vaccines: Evaluation of the safety profile.

Authors:  Claudia Maria Trombetta; Elena Gianchecchi; Emanuele Montomoli
Journal:  Hum Vaccin Immunother       Date:  2018-01-30       Impact factor: 3.452

3.  HIV-dependent depletion of influenza-specific memory B cells impacts B cell responsiveness to seasonal influenza immunisation.

Authors:  Adam K Wheatley; Anne B Kristensen; William N Lay; Stephen J Kent
Journal:  Sci Rep       Date:  2016-05-25       Impact factor: 4.379

Review 4.  Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis.

Authors:  Jenny L Schnyder; Cornelis A De Pijper; Hannah M Garcia Garrido; Joost G Daams; Abraham Goorhuis; Cornelis Stijnis; Frieder Schaumburg; Martin P Grobusch
Journal:  Travel Med Infect Dis       Date:  2020-09-06       Impact factor: 6.211

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.